MoonLake Immunotherapeutics

Overview

Compare with another stock.

• TickerMLTX on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersE9¹
• Incorporated inCayman Islands³
• Business addressDorfstrasse 29, Zug, V8 6300³
• Filer categoryLarge accelerated filer³

See how the biggest companies compare on our leaderboards

We are a clinical stage biotechnology company advancing therapies to address significant unmet needs in inflammatory skin and joint diseases. We are currently a single asset company focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, that we exclusively licensed from MHKDG and that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.⁴ From its latest annual report

Corporate structure

MoonLake Immunotherapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MoonLake Immunotherapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

Investments

Properties, in its own words

Our corporate headquarters are located in Zug, Switzerland, where we occupy approximately 4,000 square feet of office space under two open-ended office lease agreements. We use this facility for administrative purposes. In addition, we have facilities in Cambridge, UK, where we occupy approximately 6,000 square feet of office space under a 3-year term agreement set to expire in October 2026. This facility serves as working space primarily for our research and development teams. Lastly, we have facilities in Porto, Portugal, where we occupy approximately 3,900 square feet of office space under a 3-year initial term agreement set to expire in October 2026, with two extendable periods of 3 years each, the first of which we expect to exercise through October 2029, and approximately 2,000 square feet of office space under a 2-year initial term agreement set to expire in October 2026, with two extendable periods of 3 years each, the first of which we expect to exercise through October 2029. These facilities serve as working space for our general and administrative teams. We believe that our facilities are sufficient to meet our current needs. We also believe we will be able to obtain additional space, as needed, on commercially reasonable terms.

Item 2 of the 10-K filed Feb 25, 2026.⁴

Leadership

Who has led MoonLake Immunotherapeutics, and when. Pick a name to see everywhere that person has worked.

• Chief executive officerDa Silva Jorge Santos Apr 15, 2022 to now¹²
• Chief executive officerBihua Chen Oct 19, 2020 to Oct 22, 2020¹³
• ChairBihua Chen Oct 19, 2020 to Oct 22, 2020¹³
• Chief financial officerMatthias Bodenstedt Apr 15, 2022 to now¹⁴
• Chief financial officerJay Scollins Oct 19, 2020 to Oct 19, 2020¹⁵

Former names

• Helix Acquisition CorpAug 28, 2020 to Mar 31, 2022³

Timeline

1. Sep 30, 20268-K Other events²⁵
2. Aug 10, 20268-K Results of operations; Regulation FD disclosure²⁶
3. Jul 15, 20268-K Other events²⁷
4. Jun 25, 20268-K Entered a material agreement²⁸
5. Jun 22, 20268-K Regulation FD disclosure; Other events²⁹
6. Jun 9, 20268-K Executive or director change; Shareholder vote³⁰
7. Jun 1, 20268-K Entered a material agreement³¹
8. May 11, 20268-K Results of operations; Regulation FD disclosure³²
9. Feb 23, 20268-K Entered a material agreement; Results of operations; New debt or obligation³³
10. Jan 8, 20268-K Other events³⁴
11. Nov 5, 20258-K Results of operations; Regulation FD disclosure³⁵
12. Nov 5, 20258-K Entered a material agreement³⁶
13. Apr 15, 2022New chief executive Da Silva Jorge Santos becomes CEO¹²
14. Oct 19, 2020New chief executive Bihua Chen becomes CEO¹³

Calendar

Coming up

1. Nov 4, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($1.10) a share, on Nov 5, 2025.³⁷

When it reported results

1. Aug 10, 2026Reported quarterly or annual results²⁶
2. May 11, 2026Reported quarterly or annual results³²
3. Feb 23, 2026Reported quarterly or annual results³³
4. Nov 5, 2025Reported quarterly or annual results³⁵
5. Aug 5, 2025Reported quarterly or annual results³⁸
6. May 12, 2025Reported quarterly or annual results³⁹
7. Feb 26, 2025Reported quarterly or annual results⁴⁰
8. Nov 7, 2024Reported quarterly or annual results⁴¹

Drug trials and FDA: coming up

1. Jan 4, 2027Phase 3 trial readout expected Phase 3 trial of Sonelokimab and Risankizumab in Arthritis, Psoriatic: primary completion expected Jan 4, 2027 (ClinicalTrials.gov NCT06641089).⁴²

Drug trials and FDA: recently

1. May 28, 2026Phase 3 trial completed Phase 3 trial of Sonelokimab in Arthritis, Psoriatic: primary completion May 28, 2026, no results posted yet (ClinicalTrials.gov NCT06641076).⁴³
2. Sep 5, 2023Phase 2 trial completed Phase 2 trial of Sonelokimab and Adalimumab in Arthritis, Psoriatic: primary completion Sep 5, 2023, results posted Sep 10, 2026 (ClinicalTrials.gov NCT05640245).⁴⁴
3. May 9, 2023Phase 2 trial completed Phase 2 trial of Sonelokimab (M1095) and Adalimumab in Hidradenitis Suppurativa: primary completion May 9, 2023, results posted Sep 9, 2026 (ClinicalTrials.gov NCT05322473).⁴⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar

Filings

293 filings to the SEC since October 2021: 7 annual reports, 16 quarterly reports, 51 major events, 89 insider forms, 38 large holders, 92 other. The latest 20:

1. Sep 30, 20268-K CURRENT REPORT EDGAR
2. Aug 14, 2026SCHEDULE 13G EDGAR
3. Aug 14, 2026SCHEDULE 13G/A EDGAR
4. Aug 14, 2026SCHEDULE 13G/A EDGAR
5. Aug 10, 202610-Q EDGAR
6. Aug 10, 2026S-8 REGISTRATION STATEMENT EDGAR
7. Aug 10, 2026S-3ASR REGISTRATION STATEMENT EDGAR
8. Aug 10, 20268-K CURRENT REPORT EDGAR
9. Jul 29, 20264 EDGAR
10. Jul 23, 20264 EDGAR
11. Jul 21, 20264 EDGAR
12. Jul 20, 20264 EDGAR
13. Jul 15, 2026144 EDGAR
14. Jul 15, 20268-K CURRENT REPORT EDGAR
15. Jul 13, 20264 EDGAR
16. Jul 2, 20264 EDGAR
17. Jun 30, 2026144 EDGAR
18. Jun 29, 2026SCHEDULE 13D/A EDGAR
19. Jun 25, 20268-K CURRENT REPORT EDGAR
20. Jun 24, 2026424B5 PROSPECTUS SUPPLEMENT EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

56 open-market trades by officers, directors and large owners since October 2021: 10 buys and 46 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Cormorant Asset Management, LPSCHEDULE 13G/A, 3 filings Feb 17, 2026 to Aug 14, 2026⁴⁶
• Deep Track Capital, LPSCHEDULE 13G/A, 2 filings Nov 12, 2025 to Aug 14, 2026⁴⁷
• T. Rowe Price Investment Management, Inc.SCHEDULE 13G, 1 filing Aug 14, 2026⁴⁸
• BIOTECHNOLOGY VALUE FUND L PSCHEDULE 13D/A, 7 filings Apr 18, 2022 to Jun 29, 2026⁴⁹
• Avoro Capital Advisors LLCSCHEDULE 13G/A, 2 filings Aug 14, 2025 to Nov 14, 2025⁵⁰
• FMR LLCSCHEDULE 13G/A, 7 filings Dec 10, 2021 to Nov 5, 2025⁵¹
• Bihua ChenSCHEDULE 13G/A, 3 filings Mar 31, 2023 to Oct 1, 2025⁵²
• PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G/A, 4 filings Feb 14, 2022 to May 14, 2025⁵³
• Healthcare Kgaa MerckSC 13G/A, 3 filings Aug 3, 2022 to Feb 15, 2024⁵⁴
• CITADEL ADVISORS LLCSC 13G/A, 3 filings Feb 14, 2022 to Feb 14, 2024⁵⁵
• ADAGE CAPITAL PARTNERS GP, L.L.C.SC 13G/A, 1 filing Feb 9, 2023⁵⁶
• BlackRockSC 13G/A, 1 filing Feb 3, 2022⁵⁷
• RA CAPITAL MANAGEMENT, L.P.SC 13G/A, 1 filing Nov 15, 2021⁵⁸

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MoonLake Immunotherapeutics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARMoonLake Immunotherapeutics¹
• CIK0001821586
• Employer ID (EIN)98-1711963⁴
• Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company⁴
• Incorporated inCayman Islands⁴
• Fiscal year endsDecember 31¹
• Industry code (SIC)2834 Pharmaceutical Preparations¹
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance¹
• Business addressDorfstrasse 29, Zug, V8 6300¹
• Phone41 41 510 8022¹
• Shares outstanding85,106,685 as of Aug 1, 2026⁹
• Public float$1.3B as of Jun 30, 2025⁴
• AuditorBaker Tilly US, LLP, Santa Clara, California PCAOB ID 23; it also attests to the company’s internal control over financial reporting⁴
• On EDGAR sinceAug 28, 2020¹
• Filings329 in all: 4 (81), 8-K (53), 10-Q (18), 3 (16), SC 13G/A (15), CORRESP (14), UPLOAD (14), 144 (13)¹
  All 40 form types

  DEFA14A (10), SC 13G (10), SCHEDULE 13G/A (9), S-1/A (7), 10-K (6), 424B5 (6), EFFECT (6), 424B3 (5), SCHEDULE 13G (5), ARS (4), DEF 14A (4), PRER14A (4), SC 13D/A (3), SCHEDULE 13D/A (3), 10-K/A (2), POS AM (2), S-1 (2), S-3 (2), S-8 (2), 10-Q/A (1), 424B4 (1), 425 (1), 8-A12B (1), 8-K/A (1), CERT (1), DEFM14A (1), DEFR14A (1), DRS (1), NT 10-Q (1), PREM14A (1), S-3ASR (1), SC 13D (1)

• Latest filingsAnnual report (10-K) Feb 25, 2026
  Quarterly report (10-Q) Aug 10, 2026
  Proxy statement (DEF 14A) Apr 21, 2026
  Latest 8-K (8-K) Sep 30, 2026

Securities registered for trading

From the cover page of the 10-K filed Feb 25, 2026 (Section 12(b) of the Exchange Act).⁴

Risk factors and legal proceedings

The risks MoonLake Immunotherapeutics names in Item 1A of its 10-K filed Feb 25, 2026: 68 risks under these headings, as written.⁴

• Risks Related to Our Limited Operating History, Business, Financial Condition, and Results of Operations
• We have a limited operating history and have no products approved for commercial sale.
• We have incurred losses since inception, and we expect to incur significant losses for the foreseeable future and may not be able to achieve or sustain profitability in the future. We have not generated any revenue from SLK and may never generate revenue or become profitable.
• If we are unable to raise capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our development programs or future commercialization efforts, which would have a negative impact on our business, prospects, operating results and financial condition.
• Our business relies on certain licensing rights from MHKDG and RCT that can be terminated in certain circumstances. If we breach those agreements, or if we are unable to satisfy our diligence obligations under which we license rights to SLK from MHKDG, we could lose the ability to develop and commercialize SLK.
• Due to the significant resources required for the development of SLK, we must prioritize the pursuit of treatments for certain indications. We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.
• We may be required to take write-downs or write-offs, restructuring and impairment or other charges that could have a significant negative effect on our financial condition, results of operations and stock price, which could cause you to lose some or all of your investment.
• The only principal assets of our Company are cash and our interest in MoonLake AG, and accordingly we will depend on distributions from MoonLake AG to pay taxes and expenses.
• If the market opportunities for our approved product candidates, if any, are smaller than we expect, it could materially and adversely affect our financial condition and results of operation.
• Even if SLK or other compounds we may develop are successful in clinical trials and receive regulatory approvals, we or our collaboration partners may not be able to successfully commercialize them.
• The Loan and Security Agreement contains certain covenants that could adversely affect our operations and, if an event of default were to occur, we could be forced to repay any outstanding indebtedness sooner than planned and possibly at a time when we do not have sufficient capital to meet this obligation.
• Risks Related to Product Development

Legal proceedings

From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. Regardless of outcome, litigation can have an adverse impact on us due to defense and settlement costs, diversion of management resources, negative publicity, reputational harm and other factors, and there can be no assurances that favorable outcomes will be obtained.

On October 15, 2025, a lawsuit captioned Bridgewood v. MoonLake Immunotherapeutics, et al., Case No. 1:25-cv-8500 (the “Bridgewood Action”) was filed in the United States District Court for the Southern District of New York, naming the Company, its Chief Executive Officer, and its Chief Financial Officer as defendants. The Bridgewood Action was purportedly brought on behalf of a class of all investors who purchased or otherwise acquired the Company’s common stock between March 10, 2024, through September 29, 2025 (the “Class Period”). The complaint alleged claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (“Exchange Act”), based on allegedly false or misleading statements related to the clinical benefits and prospects of SLK. The lawsuit sought unspecified damages and other relief. On October 22, 2025, the plaintiff voluntarily dismissed without prejudice the Bridgewood Action.

On October 17, 2025, a second putative class action captioned Peters v. MoonLake Immunotherapeutics, et al., Case No. 1:25-cv-8612 (the “Peters Action” and, together with the Bridgewood Action, the “Class Actions”) was filed in the United States District Court for the Southern District of New York (the “Court”). The Peters Action names the same defendants, contains identical allegations of alleged violations of the Exchange Act, covers the same Class Period, and seeks the same relief as the Bridgewood Action. On January 6, 2026, the Court appointed lead plaintiff and lead counsel.

The opening of Item 3, Legal Proceedings.⁴